Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Azil Therapeutics Inc. has 2 pending office actions in Biotechnology & Pharmaceuticals. The matters are assigned to 2 examiners and 2 art units, indicating separate prosecution paths within the same technology area.
KATAKAM, SUDHAKAR is the busiest examiner, with 1 pending matter. A matter-by-matter approach is appropriate, with coordination used to maintain consistent positions across the two assignments.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Double-patenting + other | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KATAKAM, SUDHAKAR | 1 | 74.8% | +23.3% |
| BEANE, RANDALL L | 1 | 32.9% | +36.3% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17788179 | Methods for Treating Inflammatory Bowel Diseases with alpha4beta7 Integrin Antagonists | BEANE, RANDALL L | 58d overdue |
| 18139254 | METHODS FOR TREATING INFLAMMATORY BOWEL DISEASES WITH a4B7 INTEGRIN ANTAGONISTS | KATAKAM, SUDHAKAR | 44d overdue |
| Art Unit | Apps |
|---|---|
| 1658 | 1 |
| 1654 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18139254 | METHODS FOR TREATING INFLAMMATORY BOWEL DISEASES WITH a4B7 INTEGRIN ANTAGONISTS | KATAKAM, SUDHAKAR | 1658 | §103Other | Final Rejection | 44d overdue | Pending | Apr 25, 2023 |
| 17788179 | Methods for Treating Inflammatory Bowel Diseases with alpha4beta7 Integrin Antagonists | BEANE, RANDALL L | 1654 | §103§112DP | Final Rejection | 58d overdue | Pending | Jun 22, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAzil Therapeutics Inc. has 2 pending office actions as of November 2026, spread across 2 art units and 2 examiners.
Sudhakar Katakam has the most, with 1 of Azil Therapeutics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.